Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Long-Term Safety of Relacorilant for Patients with Cushing Syndrome

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the long-term safety of a treatment for Endogenous Cushing Syndrome, a condition where the body produces too much of the hormone cortisol. The treatment being studied is a medication called relacorilant, also known by its code name CORT125134. This study is an extension of previous research to further understand how safe relacorilant is for patients with this condition.

The purpose of the study is to monitor the safety of relacorilant over an extended period. Participants in the study will continue to receive relacorilant and will be regularly assessed for any side effects or changes in their health. This includes checking for any new or worsening symptoms, as well as conducting routine health checks such as blood tests, physical exams, and heart monitoring using electrocardiograms (ECGs). For those with a specific type of Cushing Syndrome caused by a pituitary tumor, magnetic resonance imaging (MRI) scans will be used to observe any changes in the tumor.

Throughout the study, participants will have regular visits to the study site to ensure their well-being and to gather important information about the effects of relacorilant. The study aims to provide valuable insights into the long-term use of relacorilant for managing the symptoms of Endogenous Cushing Syndrome, helping to improve treatment options for those affected by this condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, ensure that written informed consent is provided. This confirms understanding and agreement to participate in the study.

    If applicable, ensure the use of a highly effective method of contraception starting 30 days before entering the study and continuing until 28 days after the last dose of the study drug.

  2. Step 2

    Initial assessments

    Attend the investigative site for initial evaluations. These may include clinical laboratory tests, physical examinations, and vital sign measurements.

    For those with Cushing syndrome due to a pituitary tumor, obtain a pituitary MRI or CT scan to assess changes in tumor size. This can be done up to 6 months before starting treatment or up to 6 weeks after starting treatment.

  3. Step 3

    Medication administration

    Begin taking the study drug, relacorilant, as prescribed by the study team. The dosage and frequency will be determined by the study protocol and communicated by the healthcare provider.

  4. Step 4

    Ongoing monitoring

    Attend monthly visits to the investigative site for monitoring. This includes assessments for any treatment-emergent adverse events, changes in laboratory tests, physical examinations, and vital sign measurements.

    Undergo regular electrocardiograms (ECGs) to monitor heart function, including measurements of the QTcF interval, QRS complex, PR interval, and heart rate.

  5. Step 5

    End of study procedures

    Upon completion of the study, final evaluations will be conducted. These may include laboratory tests, physical examinations, and imaging studies to assess the overall impact of the treatment.

    Ensure that any required follow-up actions, such as continued use of contraception, are completed as instructed by the study team.

Who can join the trial?

9 criteria

  • Have completed a Corcept-sponsored study of relacorilant in **endogenous Cushing syndrome**.
  • According to the doctor's opinion, will benefit from treatment with **relacorilant**.
  • Provide written informed consent, which means you agree to participate after understanding the study details.
  • If you are a female who can have children, you must be willing to use a highly effective method of birth control from 30 days before starting the study until 28 days after the last dose of the study drug. Male participants with a female partner must agree to use 2 forms of birth control, one of which must be a double-barrier method, from study entry until 28 days after the last dose of the study drug.
  • Are willing to avoid using drugs that affect hormone production by the adrenal glands or hormone release by a tumor.
  • Are able to return to the study site to complete the required evaluations.
  • If you have Cushing syndrome due to a tumor in the pituitary gland, you must be able to have an MRI scan of the pituitary gland (up to 6 months before starting treatment in this study, or up to 6 weeks after starting treatment in this study) to check for changes in tumor size. A CT scan can be used instead if an MRI is not suitable for you.
  • If you are entering the study more than 12 weeks after completing the last dose in the previous study, confirmation of high cortisol levels consistent with the criteria of the previous study is required.
  • If you received treatment for high cortisol levels after your last dose in the previous study, confirmation of high cortisol levels consistent with the criteria of the previous study is required.

Who cannot join the trial?

10 criteria

  • Patients with any other serious health condition that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial within the last 30 days.
  • Patients who have a known allergy to the study medication or its ingredients.
  • Patients who are unable to follow the study procedures or attend the required visits.
  • Patients with a history of drug or alcohol abuse within the past year.
  • Patients who have had major surgery within the last 30 days.
  • Patients with uncontrolled high blood pressure.
  • Patients with severe liver or kidney disease.
  • Patients with a history of certain heart conditions.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Relacorilant is a medication being studied for its potential to help people with a condition called endogenous Cushing syndrome. This condition happens when the body produces too much of a hormone called cortisol, which can lead to various health problems. Relacorilant works by blocking the effects of cortisol, which may help reduce the symptoms and signs of this syndrome. The clinical trial is focused on understanding how safe it is to use relacorilant over a long period for treating this condition.

What is already known about the treatment

Relacorilant – Relacorilant is administered orally in the form of tablets and is currently being studied for its safety in treating endogenous Cushing syndrome, a condition where the body produces too much cortisol. This medication is in the clinical trial phase, and researchers are evaluating its long-term safety and effectiveness. Relacorilant works by blocking the effects of cortisol at the molecular level, helping to reduce the symptoms associated with excess cortisol. It is classified as a glucocorticoid receptor antagonist, which means it interferes with the action of cortisol, a stress hormone, to help manage the symptoms of the syndrome.

Investigated diseases

Endogenous Cushing Syndrome – This disease is characterized by the overproduction of cortisol by the adrenal glands, often due to a pituitary tumor that secretes excess adrenocorticotropic hormone (ACTH). The progression of the disease involves a range of symptoms such as weight gain, particularly around the abdomen and face, thinning skin, and easy bruising. Muscle weakness and fatigue are common as the condition advances. Patients may also experience high blood pressure and changes in mood or mental health. Over time, the excess cortisol can lead to complications like osteoporosis and type 2 diabetes. The disease requires careful monitoring to manage its symptoms and prevent further complications.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2024-514079-17-00Protocol codeCORT125134-452Estimated enrolment139 patientsSponsorCorcept Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.